Market Overview

Factors of Influence in 2018, Key Indicators and Opportunity within Intersect ENT, Akari Therapeutics, Ampio Pharmaceuticals, Virtusa, Umpqua, and Hamilton Lane — New Research Emphasizes Economic Growth

Share:

NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Intersect ENT, Inc. (NASDAQ:XENT), Akari Therapeutics PLC (NASDAQ:AKTX), Ampio Pharmaceuticals, Inc. (NYSE:AMPE), Virtusa Corporation (NASDAQ:VRTU), Umpqua Holdings Corporation (NASDAQ:UMPQ), and Hamilton Lane Inc. (NASDAQ:HLNE), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

XENT DOWNLOAD: http://MarketSourceResearch.com/register/?so=XENT
AKTX DOWNLOAD: http://MarketSourceResearch.com/register/?so=AKTX
AMPE DOWNLOAD: http://MarketSourceResearch.com/register/?so=AMPE
VRTU DOWNLOAD: http://MarketSourceResearch.com/register/?so=VRTU
UMPQ DOWNLOAD: http://MarketSourceResearch.com/register/?so=UMPQ
HLNE DOWNLOAD: http://MarketSourceResearch.com/register/?so=HLNE

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Market Source Research, available for free download at the links above, examine Intersect ENT, Inc. (NASDAQ:XENT), Akari Therapeutics PLC (NASDAQ:AKTX), Ampio Pharmaceuticals, Inc. (NYSE:AMPE), Virtusa Corporation (NASDAQ:VRTU), Umpqua Holdings Corporation (NASDAQ:UMPQ), and Hamilton Lane Inc. (NASDAQ:HLNE) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed October 23rd, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

INTERSECT ENT, INC. (XENT) REPORT OVERVIEW

Intersect ENT's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Intersect ENT reported revenue of $26.30MM vs $23.99MM (up 9.65%) and analysts estimated basic earnings per share -$0.14 vs -$0.08. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Intersect ENT reported revenue of $96.30MM vs $78.71MM (up 22.35%) and analysts estimated basic earnings per share -$0.56 vs -$0.89. Analysts expect earnings to be released on November 5th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.15. The estimated EPS forecast for the next fiscal year is -$0.54 and is expected to report on February 26th, 2019.

To read the full Intersect ENT, Inc. (XENT) report, download it here: http://MarketSourceResearch.com/register/?so=XENT

-----------------------------------------

AKARI THERAPEUTICS PLC (AKTX) REPORT OVERVIEW

Akari Therapeutics' Recent Financial Performance

Analysts expect earnings to be released on November 12th, 2018. The report will be for the fiscal period ending September 30th, 2018. Reported EPS for the same quarter last year was -$0.09. The estimated EPS forecast for the next fiscal year is -$1.00 and is expected to report on March 20th, 2019.

To read the full Akari Therapeutics PLC (AKTX) report, download it here: http://MarketSourceResearch.com/register/?so=AKTX

-----------------------------------------

AMPIO PHARMACEUTICALS, INC. (AMPE) REPORT OVERVIEW

Ampio Pharmaceuticals' Recent Financial Performance

Analysts expect earnings to be released on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018.

To read the full Ampio Pharmaceuticals, Inc. (AMPE) report, download it here: http://MarketSourceResearch.com/register/?so=AMPE

-----------------------------------------

VIRTUSA CORPORATION (VRTU) REPORT OVERVIEW

Virtusa's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Virtusa reported revenue of $300.03MM vs $227.35MM (up 31.97%) and basic earnings per share -$0.25 vs $0.10. For the twelve months ended March 31st, 2018 vs March 31st, 2017, Virtusa reported revenue of $1,020.67MM vs $858.73MM (up 18.86%) and analysts estimated basic earnings per share -$0.09 vs $0.40. Analysts expect earnings to be released on November 14th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.22. The estimated EPS forecast for the next fiscal year is $2.06 and is expected to report on May 21st, 2019.

To read the full Virtusa Corporation (VRTU) report, download it here: http://MarketSourceResearch.com/register/?so=VRTU

-----------------------------------------

UMPQUA HOLDINGS CORPORATION (UMPQ) REPORT OVERVIEW

Umpqua's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Umpqua reported interest income of $255.19MM vs $231.80MM (up 10.09%) and analysts estimated basic earnings per share $0.30 vs $0.26 (up 15.38%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Umpqua reported interest income of $938.10MM vs $910.64MM (up 3.02%) and analysts estimated basic earnings per share $1.12 vs $1.06 (up 5.66%). Analysts expect earnings to be released on January 22nd, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.31. The estimated EPS forecast for the next fiscal year is $1.65 and is expected to report on January 22nd, 2019.

To read the full Umpqua Holdings Corporation (UMPQ) report, download it here: http://MarketSourceResearch.com/register/?so=UMPQ

-----------------------------------------

HAMILTON LANE INC. (HLNE) REPORT OVERVIEW

Hamilton Lane's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Hamilton Lane reported revenue of $63.36MM vs $52.70MM (up 20.23%) and analysts estimated basic earnings per share $0.40 vs $0.30 (up 33.33%). For the twelve months ended March 31st, 2018 vs March 31st, 2017, Hamilton Lane reported revenue of $244.03MM vs $179.82MM (up 35.71%) and analysts estimated basic earnings per share $0.94 vs $0.03 (up 3,033.33%). Analysts expect earnings to be released on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.27. The estimated EPS forecast for the next fiscal year is $2.07 and is expected to report on June 6th, 2019.

To read the full Hamilton Lane Inc. (HLNE) report, download it here: http://MarketSourceResearch.com/register/?so=HLNE

-----------------------------------------

ABOUT MARKET SOURCE RESEARCH

Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

REGISTERED MEMBER STATUS

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Hugo Moreau, Media Department
Office: +1 (704) 343-6361
E-mail: media@MarketSourceResearch.com

© 2018 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@MarketSourceResearch.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

 

View Comments and Join the Discussion!